Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Temodal (temozolomide) Post Marketing Surveillance Protocol.

Trial Profile

Temodal (temozolomide) Post Marketing Surveillance Protocol.

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Dec 2013

At a glance

  • Drugs Temozolomide (Primary)
  • Indications Anaplastic astrocytoma; Glioblastoma; Glioma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 08 May 2012 Actual patient number is 682 according to ClinicalTrials.gov.
    • 03 Jan 2012 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov.
    • 03 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top